Местные эстрогены в лечении вагинальной атрофии

Abstract

Menopausal urogenital syndrome (MMC), formerly known as vulvovaginal atrophy, atrophic vaginitis, or urogenital atrophy, is characterized by clinical symptoms secondary to their clinical manifestation. Genitourinary syndrome during menopause is a hypoestrogenic condition with consequences that affect the condition of the external genital organs, have an impact on sex life and the work of the urinary organs. In one way or another, the symptoms of MMC are manifested in a large number of women: they are noted by approximately 15% of women who were interviewed during the premenopausal period and about 40–54% of the patients during the postmenopausal period. In connection with life expectancy, which is increasing worldwide, this group of women will also expand at the expense of a group of patients over 65 years old, whose share will be 1/6 of the population by the next decade of the 21st century. Thus, MMS is a complex disease, the presence of which is necessary for professionals to know in order to inform the patient in time in order to avoid long-term risks. Selection of therapy is always a balance between eliminating a medical problem, taking into account the risk profile for patients and improving their quality of life. Key words: menopausal urogenital syndrome, atrophic vaginitis, urinary incontinence, chronic cystitis, local estrogens.